TrialJournal of gastroenterology and hepatology2022

Adrenomedullin for biologic-resistant Crohn's disease: A randomized, double-blind, placebo-controlled phase 2a clinical trial.

Toshihiro Kita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.